Instem is a leading provider of IT solutions & services to the life sciences market. Instem's software enables its customers (mainly pharmaceutical companies) to bring their life-enhancing drugs to market faster.
Instem came to market in 2010 with a compelling story based on dominance of a niche market, good recurring revenues and strong cash generation. In our view, the group has a strong track record of delivery, and the favourable market backdrop gives further confidence in the growth story.
Instem has once again delivered a strong set of interim results, in our view, with the outcome consistent […]
Instem has signed its largest ever single contract, a five-year $12m deal with a leading global contract research […]
Instem’s update for the six months to 30 June 2022 (H1 22) confirms that the business continues to […]
Instem has reported FY21 results consistent with the January trading statement and in line with our forecasts. Despite […]
Instem offers an opportunity to invest in a business with two specific attractions – (1) The group is […]
Instem has delivered a positive trading update for the year to 31 December 2021, reporting like-for-like (LFL) revenue […]
Instem has once again delivered a strong set of interim results in our view, with the growth story […]
Instem has announced the (earnings enhancing) acquisition of PDS Pathology Data Systems Ltd (“PDS”) a Swiss-based life sciences […]
Instem’s update for the six months to 30 June 2021 (H1 21E) confirms that trading was in line […]
Company Management Team
Chief Executive Officer
Phil has been leading Instem as CEO since 1995, working closely with the Instem Board, investors, management, clients, partners and staff to grow the business from a single product line with fifteen clients to serving hundreds of customers as the global market leader across a wide area of life sciences R&D. Passionate about Instem’s ability to support clients in introducing transformational approaches for life changing therapies, Phil has been a vocal advocate of long-term partnerships, innovative organic growth, geographic expansion and the acquisitive consolidation of the fragmented IT supplier community. Under Phil’s leadership Instem has completed the strategic acquisition of 7 companies, has opened new offices in the US, UK, China, and India and has completed a UK-based IPO in 2010.
Chief Financial Officer
Nigel joined Instem in November of 2011 and possesses a wealth of experience in senior financial roles at both public and private companies within the life sciences industry. Prior to Instem, Nigel was Finance Director for 3 years at the AIM listed, pharmaceutical and medical devices company, IS Pharma plc. He also held the position of CFO for 7 years at Almedica International Inc., a privately held supplier of clinical trial materials to the global pharmaceutical and biotech markets and 2 years as European Controller for the sales and marketing division of laboratory equipment manufacturer, Life Sciences International plc. Prior to entering industry, Nigel spent over 9 years at KPMG and is a qualified Chartered Accountant.